Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

479
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
479
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computed Tomography-Based Assessment of Sarcopenia and Disease Progression in Pancreatic Ductal Adenocarcinoma: A Radiomics and Machine Learning Approach.

Gastroenterology research·2026
Same author

Safety and preliminary activity of neoadjuvant trastuzumab deruxtecan (T-DXd) plus 5-fluorouracil and folinic acid for HER2-positive, resectable esophagogastric adenocarcinoma: Results from the safety run-in cohort of the phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART trial.

Oncology research and treatment·2026
Same author

Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).

Therapeutic advances in medical oncology·2026
Same author

Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.

Nature medicine·2025
Same author

Interest in complementary and alternative medicine among participants in a study on cancer prevention by green tea extract - results from an expert-based survey of MIRACLE trial participants.

BMC complementary medicine and therapies·2025
Same author

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.

Liver international : official journal of the International Association for the Study of the Liver·2025

Related Experiment Video

Updated: Mar 28, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K

Pancreatic Cancer: Progress in Systemic Therapy.

Luka Perkhofer1, Thomas J Ettrich1, Thoma Seufferlein1

  • 1Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.

Gastrointestinal Tumors
|December 18, 2015
PubMed
Summary

Pancreatic cancer chemotherapy is evolving, with novel regimens like FOLFIRINOX and gemcitabine plus albumin-bound paclitaxel showing improved outcomes over standard gemcitabine. Targeted therapies are also under investigation for pancreatic ductal adenocarcinoma (PDAC).

Keywords:
ChemotherapyPancreasPancreatic cancerTherapy

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

897
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

13.1K

Related Experiment Videos

Last Updated: Mar 28, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

897
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

13.1K

Area of Science:

  • Oncology
  • Medical Chemistry

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer mortality.
  • Delayed diagnosis due to non-specific symptoms leads to advanced disease at presentation.
  • Systemic therapy is crucial for the majority of PDAC patients.

Purpose of the Study:

  • To review current chemotherapy regimens for pancreatic cancer.
  • To provide an outlook on future therapeutic strategies for PDAC.

Main Methods:

  • Review of current literature on pancreatic cancer chemotherapy.
  • Analysis of neoadjuvant and first-line/second-line treatment approaches.
  • Evaluation of novel chemotherapeutic regimens and targeted therapies.

Main Results:

  • Standard chemotherapy for PDAC includes gemcitabine or 5-fluorouracil.
  • Novel regimens like FOLFIRINOX and gemcitabine plus nanoparticle albumin-bound paclitaxel demonstrate superior efficacy compared to standard gemcitabine.
  • Combination of erlotinib plus gemcitabine shows benefit in first-line metastatic treatment.

Conclusions:

  • Understanding molecular characteristics aids in identifying therapeutic targets for PDAC.
  • Targeted therapies are being evaluated in clinical trials.
  • Future perspectives include novel agents like S-1 and combination therapies.